{"GPL9741": [{"GSM478534": [{"title": "Patient 1, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 47;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 2.5;\tedss after 1 year: 3.0;\tedss after 2 years: 3.0;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 1;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): 7;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478535": [{"title": "Patient 1, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 47;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 2.5;\tedss after 1 year: 3.0;\tedss after 2 years: 3.0;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 1;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): 7;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478536": [{"title": "Patient 1, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 47;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 2.5;\tedss after 1 year: 3.0;\tedss after 2 years: 3.0;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 1;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): 7;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478537": [{"title": "Patient 2, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 45;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 1.5;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478538": [{"title": "Patient 2, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 45;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 1.5;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478539": [{"title": "Patient 2, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 45;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 1.5;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478540": [{"title": "Patient 3, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 30;\tduration from ms diagnosis to therapy initiation (in months): 8;\tedss at baseline: 2.5;\tedss after 1 year: 2.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 2;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478541": [{"title": "Patient 3, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 30;\tduration from ms diagnosis to therapy initiation (in months): 8;\tedss at baseline: 2.5;\tedss after 1 year: 2.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 2;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478542": [{"title": "Patient 3, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 30;\tduration from ms diagnosis to therapy initiation (in months): 8;\tedss at baseline: 2.5;\tedss after 1 year: 2.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 2;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478543": [{"title": "Patient 4, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 40;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: 2;\ttime from start of therapy to the first relapse (in months): 15;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478544": [{"title": "Patient 4, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 40;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: 2;\ttime from start of therapy to the first relapse (in months): 15;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478545": [{"title": "Patient 4, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 40;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: 2;\ttime from start of therapy to the first relapse (in months): 15;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478546": [{"title": "Patient 5, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 28;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.5;\tedss after 1 year: 2.5;\tedss after 2 years: 6.0;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 2;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 13;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478547": [{"title": "Patient 5, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 28;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.5;\tedss after 1 year: 2.5;\tedss after 2 years: 6.0;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 2;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 13;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478548": [{"title": "Patient 5, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 28;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.5;\tedss after 1 year: 2.5;\tedss after 2 years: 6.0;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 2;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 13;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478549": [{"title": "Patient 6, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 31;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478550": [{"title": "Patient 6, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 31;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478551": [{"title": "Patient 6, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 31;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478552": [{"title": "Patient 7, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 44;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 2.0;\tedss after 5 years: 4.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 7;\ttime from start of therapy to the first relapse (in months): 28;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478553": [{"title": "Patient 7, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 44;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 2.0;\tedss after 5 years: 4.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 7;\ttime from start of therapy to the first relapse (in months): 28;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478554": [{"title": "Patient 7, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 44;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 2.0;\tedss after 5 years: 4.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 7;\ttime from start of therapy to the first relapse (in months): 28;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478555": [{"title": "Patient 8, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 45;\tduration from ms diagnosis to therapy initiation (in months): 96;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478556": [{"title": "Patient 8, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 45;\tduration from ms diagnosis to therapy initiation (in months): 96;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478557": [{"title": "Patient 8, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 45;\tduration from ms diagnosis to therapy initiation (in months): 96;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478558": [{"title": "Patient 9, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 24;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 0.0;\tedss after 5 years: 0.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478559": [{"title": "Patient 9, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 24;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 0.0;\tedss after 5 years: 0.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478560": [{"title": "Patient 9, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 24;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 0.0;\tedss after 5 years: 0.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478561": [{"title": "Patient 10, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 44;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478562": [{"title": "Patient 10, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 44;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478563": [{"title": "Patient 10, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 44;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 2.5;\tedss after 5 years: 2.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478564": [{"title": "Patient 11, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 43;\tduration from ms diagnosis to therapy initiation (in months): 4;\tedss at baseline: 1.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 2"}]}, {"GSM478565": [{"title": "Patient 11, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 43;\tduration from ms diagnosis to therapy initiation (in months): 4;\tedss at baseline: 1.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 2"}]}, {"GSM478566": [{"title": "Patient 11, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 43;\tduration from ms diagnosis to therapy initiation (in months): 4;\tedss at baseline: 1.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 2"}]}, {"GSM478567": [{"title": "Patient 12, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 27;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.5;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478568": [{"title": "Patient 12, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 27;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.5;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478569": [{"title": "Patient 12, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 27;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.5;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478570": [{"title": "Patient 13, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 39;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 0.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478571": [{"title": "Patient 13, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 39;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 0.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478572": [{"title": "Patient 13, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 39;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 0.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478573": [{"title": "Patient 14, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 22;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 2;\tnumber of relapses during 5-year follow-up: 2;\ttime from start of therapy to the first relapse (in months): 5;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478574": [{"title": "Patient 14, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 22;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 2;\tnumber of relapses during 5-year follow-up: 2;\ttime from start of therapy to the first relapse (in months): 5;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478575": [{"title": "Patient 14, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 22;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 2;\tnumber of relapses during 5-year follow-up: 2;\ttime from start of therapy to the first relapse (in months): 5;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478576": [{"title": "Patient 15, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 34;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: NA;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: NA;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): >12;\tcompleted years of ifn-beta therapy: 0"}]}, {"GSM478577": [{"title": "Patient 15, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 34;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: NA;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: NA;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): >12;\tcompleted years of ifn-beta therapy: 0"}]}, {"GSM478578": [{"title": "Patient 15, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 34;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: NA;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: NA;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): >12;\tcompleted years of ifn-beta therapy: 0"}]}, {"GSM478579": [{"title": "Patient 16, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 20;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.5;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 2;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 3;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): 5;\tcompleted years of ifn-beta therapy: >=4"}]}, {"GSM478580": [{"title": "Patient 16, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 20;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.5;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 2;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 3;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): 5;\tcompleted years of ifn-beta therapy: >=4"}]}, {"GSM478581": [{"title": "Patient 16, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 20;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 1.5;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: NA;\tnumber of relapses during the year prior to treatment: 2;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 3;\tnumber of relapses during 5-year follow-up: NA;\ttime from start of therapy to the first relapse (in months): 5;\tcompleted years of ifn-beta therapy: >=4"}]}, {"GSM478582": [{"title": "Patient 17, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 30;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478583": [{"title": "Patient 17, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 30;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478584": [{"title": "Patient 17, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 30;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 1.0;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478585": [{"title": "Patient 18, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 38;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 0.5;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 0.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478586": [{"title": "Patient 18, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 38;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 0.5;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 0.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478587": [{"title": "Patient 18, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 38;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 0.5;\tedss after 1 year: 1.0;\tedss after 2 years: 1.0;\tedss after 5 years: 0.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478588": [{"title": "Patient 19, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 41;\tduration from ms diagnosis to therapy initiation (in months): 3;\tedss at baseline: 1.5;\tedss after 1 year: 2.0;\tedss after 2 years: 2.0;\tedss after 5 years: 4.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 3;\tnumber of relapses during 2-year follow-up: 4;\tnumber of relapses during 5-year follow-up: 5;\ttime from start of therapy to the first relapse (in months): 2;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478589": [{"title": "Patient 19, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 41;\tduration from ms diagnosis to therapy initiation (in months): 3;\tedss at baseline: 1.5;\tedss after 1 year: 2.0;\tedss after 2 years: 2.0;\tedss after 5 years: 4.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 3;\tnumber of relapses during 2-year follow-up: 4;\tnumber of relapses during 5-year follow-up: 5;\ttime from start of therapy to the first relapse (in months): 2;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478590": [{"title": "Patient 19, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 41;\tduration from ms diagnosis to therapy initiation (in months): 3;\tedss at baseline: 1.5;\tedss after 1 year: 2.0;\tedss after 2 years: 2.0;\tedss after 5 years: 4.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 3;\tnumber of relapses during 2-year follow-up: 4;\tnumber of relapses during 5-year follow-up: 5;\ttime from start of therapy to the first relapse (in months): 2;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478591": [{"title": "Patient 20, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 35;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478592": [{"title": "Patient 20, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 35;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478593": [{"title": "Patient 20, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 35;\tduration from ms diagnosis to therapy initiation (in months): 2;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 0;\ttime from start of therapy to the first relapse (in months): >60;\tcompleted years of ifn-beta therapy: 1"}]}, {"GSM478594": [{"title": "Patient 21, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 38;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 2.0;\tedss after 1 year: 1.5;\tedss after 2 years: 3.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 3;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 6;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478595": [{"title": "Patient 21, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 38;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 2.0;\tedss after 1 year: 1.5;\tedss after 2 years: 3.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 3;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 6;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478596": [{"title": "Patient 21, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 38;\tduration from ms diagnosis to therapy initiation (in months): 1;\tedss at baseline: 2.0;\tedss after 1 year: 1.5;\tedss after 2 years: 3.0;\tedss after 5 years: 1.0;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 2;\tnumber of relapses during 2-year follow-up: 3;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 6;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478597": [{"title": "Patient 22, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 49;\tduration from ms diagnosis to therapy initiation (in months): 6;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 1;\ttime from start of therapy to the first relapse (in months): 43;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478598": [{"title": "Patient 22, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 49;\tduration from ms diagnosis to therapy initiation (in months): 6;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 1;\ttime from start of therapy to the first relapse (in months): 43;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478599": [{"title": "Patient 22, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 49;\tduration from ms diagnosis to therapy initiation (in months): 6;\tedss at baseline: 0.0;\tedss after 1 year: 0.0;\tedss after 2 years: 1.0;\tedss after 5 years: 2.0;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 1;\ttime from start of therapy to the first relapse (in months): 43;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478600": [{"title": "Patient 23, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 26;\tduration from ms diagnosis to therapy initiation (in months): 36;\tedss at baseline: 1.0;\tedss after 1 year: 2.0;\tedss after 2 years: 1.5;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 1;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 7;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478601": [{"title": "Patient 23, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 26;\tduration from ms diagnosis to therapy initiation (in months): 36;\tedss at baseline: 1.0;\tedss after 1 year: 2.0;\tedss after 2 years: 1.5;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 1;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 7;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478602": [{"title": "Patient 23, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: male;\tage at ifn-beta therapy onset (baseline blood sampling): 26;\tduration from ms diagnosis to therapy initiation (in months): 36;\tedss at baseline: 1.0;\tedss after 1 year: 2.0;\tedss after 2 years: 1.5;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 0;\tnumber of relapses during 1-year follow-up: 1;\tnumber of relapses during 2-year follow-up: 1;\tnumber of relapses during 5-year follow-up: 3;\ttime from start of therapy to the first relapse (in months): 7;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478603": [{"title": "Patient 24, before first IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 40;\tduration from ms diagnosis to therapy initiation (in months): 134;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 1;\ttime from start of therapy to the first relapse (in months): 55;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478604": [{"title": "Patient 24, before second IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 40;\tduration from ms diagnosis to therapy initiation (in months): 134;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 1;\ttime from start of therapy to the first relapse (in months): 55;\tcompleted years of ifn-beta therapy: >=5"}]}, {"GSM478605": [{"title": "Patient 24, before fifth IFN-beta injection U133A"}, {"type": "RNA"}, {"source_name_ch1": "Peripheral blood mononuclear cells"}, {"characteristics_ch1": "gender: female;\tage at ifn-beta therapy onset (baseline blood sampling): 40;\tduration from ms diagnosis to therapy initiation (in months): 134;\tedss at baseline: 1.5;\tedss after 1 year: 1.5;\tedss after 2 years: 1.0;\tedss after 5 years: 1.5;\tnumber of relapses during the year prior to treatment: 1;\tnumber of relapses during 1-year follow-up: 0;\tnumber of relapses during 2-year follow-up: 0;\tnumber of relapses during 5-year follow-up: 1;\ttime from start of therapy to the first relapse (in months): 55;\tcompleted years of ifn-beta therapy: >=5"}]}]}